Investment Structure

Targepeutics, Inc. is a biopharmaceutical company developing selective molecularly targeted therapeutics to fight cancer and other dreaded diseases. Targepeutics has licensed a broad platform of anticancer technologies with the leading arm based on re-engineered Interleukin 13 that targets receptors overexpressed specifically on cancer cells. Targepeutics has also licensed technologies for the treatment, as well as the imaging and diagnosis of brain tumors.

Our lead compound GB-13 is genetically engineered recombinant protein that specifically binds and destroys cancer cells with minimal normal cell damage.

Our Unique DiscoveryTargepeutics’ genesis was the decision of its founder, Waldemar Debinski not to pursue investment funding for his discovery that IL-13 could be developed into a cancer-targeting compound. While another company picked up licensing rights for this naturally occurring compound, Dr. Debinski decided to go back to work in his lab as he was scientifically unsatisfied with the compound’s remaining affinity to bind with normal cells. After substantial development, Dr. Debinski successfully mutated two new generations of IL-13 compounds that have very little affinity to bind with normal cells.Dr. Debinski’s completion of this development will allow Targepeutics to move its lead compound, GB-13, into Phase I clinical trials for high-grade glioma (brain cancer) with only $4 million of initial capital. The Company is now seeking additional equity investments to advance GB-13 into Phase II clinical trials and bring a second compound, a vaccine and imaging reagents to clinical trials. By any measure, these sums are extraordinarily low for bringing a compound this deeply into clinical trials. Targepeutics will use preliminary GB-13 Phase II results to recruit management, scientists, and hold a $10-15 million mezzanine round to set up facilities and complete further clinical trials.
Management & Advisors:Silvan B. Lutkewitte, III President and C.E.O.; has over 15 years in starting, financing and operating several successful businesses. Sil’s background is in Corporate Finance with Deloitte and Touche, including mergers and acquisitions, valuations, financing, tax and accounting matters.

Lynn W. Maines, Ph.D., M.B.A.  Co-founder, Vice President, Business Development and Operations; served as a Fellow at Penn State’s Office of Technology Transfer evaluating medical technology for commercial application; has overseen entire formation of Targepeutics’ corporate structure from inception.

Waldemar Debinski, M.D., Ph.D.  Co-founder and Consulting Scientific Officer; Director of The Brain Tumor Center of Excellence, Wake Forest University; leading authority on receptor-specific chimeric proteins expressed by tumor cells and immunological aspects of cancer treatment; distinguished academic and scientific career at the National Institutes of Health and Clinical Research Institute of Montreal and Hotel-Dieu Hospital; author of nearly 200 scientific reports; received the Excellence in Basic Research Award in 2000 from the Society for Neuro-Oncology.

Gerard C. Smith, CFA  Financial Advisor; Managing Director of Equities, Public School Employees Retirement System; responsible for over $14 billion of internally managed equities, over 20 years public equity and venture capital experience.

Akiva Mintz, M.D.-Ph.D., Vice President of Research and Development. Dr. Mintz has spent 10 years developing various cancer-targeted therapies and imaging tracers. He trained under the mentorship of Dr. Debisnki where he co-developed some novel anti-IL13Ra2 targeted therapies. Completed a clinical internship and a 2 year NIH-sponsored Molecular Imaging fellowship at the University of Pennsylvania with a focus on multimodality molecular imaging of cancer. Has also passed all three Chartered Financial Analyst exams.

Alfred W. Alberts, Ph.D. Consultant specializing in drug discovery and development.  He retired in 1995 from Merck Research Laboratories where his most recent position was Vice President, Biochemistry and Director of Natural Product Drug Discovery.  While at Merck he directed programs in atherosclerosis, diabetes and obesity.  He was responsible for the discovery and development of lovastatin (Mevacor) and simvastatin (Zocor).    He is the recipient of a number of honors including the Pharmaceutical Manufacturers Association Discoverers Award, the “Inventor of the Year” award granted by the Intellectual Property Owners, Inc., the “Thomas Alva Edison” Award, the Merck Director’s Award and an honorary Doctor of Science from the University of Maryland.

  Technology License Agreement Targepeutics’ entire technology portfolio has been exclusively licensed from the Pennsylvania State University, which owns all patent filings.


With manufacturing of their first compound complete, Targepeutics’ path to clinical trials is clear. Coupled with their entire portfolio of compounds, Targepeutics’ future looks extraordinary.